MARKET

GNFT

GNFT

GENFIT S.A.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.33
+0.12
+2.30%
Closed 16:00 07/15 EDT
OPEN
5.31
PREV CLOSE
5.21
HIGH
5.39
LOW
5.28
VOLUME
22.93K
TURNOVER
--
52 WEEK HIGH
22.48
52 WEEK LOW
5.10
MARKET CAP
207.02M
P/E (TTM)
-2.4171
1D
5D
1M
3M
1Y
5Y

GNFT News

More
The Daily Biotech Pulse: Moderna To Kickstart Phase 3 Study On July 27, Immutep Awarded Antibody Patent
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 14)
Benzinga · 13h ago
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
GlobeNewswire · 5d ago
Intercept's Pain Is Galectin's Gain: Clinical Outcomes In NASH Are Crucial
Seeking Alpha - Article · 07/07 12:30
Intercept Pharmaceuticals: Regulatory Snub Unsettles Liver Therapy Front-Runner
Seeking Alpha - Article · 07/05 09:41
Intercept Slumps as the FDA Issues CRL to NASH Candidate
Zacks · 06/30 15:29
Intercept Shares Tumble on NASH Disappointment
Barrons.com · 06/29 21:05
B of A Securities Initiates Coverage On Genfit with Underperform Rating, Announces Price Target of $7
B of A Securities analyst Geoff Meacham initiates coverage on Genfit (NASDAQ:GNFT) with a Underperform rating and announces Price Target of $7.
Benzinga · 06/25 12:32
Inventiva files for IPO
Seeking Alpha - Article · 06/19 21:01

Industry

Biotechnology & Medical Research
+1.30%
Pharmaceuticals & Medical Research
+1.59%

Hot Stocks

Symbol
Price
%Change

About GNFT

Genfit SA is a France-based biopharmaceutical company that specializes in the development of medicines for the prevention and treatment of diabetes and related disorders. The Company is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the inflammatory bowel disease. The Company targets a number of therapeutic areas, which includes nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), NASH diagnosis, NASH-induced fibrosis and IL-17 dependent autoimmune diseases. The Company’s research programs develop diversified pipeline of drug candidates, including Elafibranor in NASH, which is in phase III; Elafibranor in PBC, which is in phase II; In-Vitro diagnostic test for NASH and Nitazoxanide in fibrosis, which is still in clinical stage, among others.
More

Webull offers kinds of Genfit SA (ADR) stock information, including NASDAQ:GNFT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GNFT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GNFT stock methods without spending real money on the virtual paper trading platform.